{"id":3663,"date":"2023-06-14T22:35:19","date_gmt":"2023-06-14T20:35:19","guid":{"rendered":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/correction-ipsen-announces-u-s-fda-submission-acceptance-of-its-supplemental-new-drug-application-for-onivyde-regimen-in-first-line-metastatic-pancreatic-ductal-adenocarcinoma\/"},"modified":"2023-06-14T22:35:19","modified_gmt":"2023-06-14T20:35:19","slug":"correction-ipsen-announces-u-s-fda-submission-acceptance-of-its-supplemental-new-drug-application-for-onivyde-regimen-in-first-line-metastatic-pancreatic-ductal-adenocarcinoma","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/correction-ipsen-announces-u-s-fda-submission-acceptance-of-its-supplemental-new-drug-application-for-onivyde-regimen-in-first-line-metastatic-pancreatic-ductal-adenocarcinoma\/","title":{"rendered":"Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma"},"content":{"rendered":"